Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds RSS Feed PharmiWeb Candidate Blog RSS Feed PharmiWeb Client Blog


Press Release

Taro Announces Completion of $250 Million Share Repurchase Program

Taro Pharmaceutical Industries Ltd.
Posted on: 19 Aug 16

Taro Pharmaceutical Industries Ltd. (NYSE:TARO) announced today that it recently completed its $250 million share repurchase program. The company bought back 1,801,099 of its ordinary shares in open market transactions at an average price of $138.80 per share. The repurchase program was announced by the company on March 15, 2016, and was completed on August 18, 2016.

About Taro

Taro Pharmaceutical Industries Ltd. is a multinational, science-based pharmaceutical company, dedicated to meeting the needs of its customers through the discovery, development, manufacturing and marketing of the highest quality healthcare products. For further information on Taro Pharmaceutical Industries Ltd., please visit the Company’s website at

View source version on

Business Wire

Last updated on: 19/08/2016

Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.